KCA
Search
- Page Path
- HOME > Search
Original Article
- Breast cancer
- PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
- Ju Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Park
- Cancer Res Treat. 2023;55(2):531-541. Published online September 7, 2022
- DOI: https://doi.org/10.4143/crt.2022.221
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Mutations in the PIK3CA gene occur frequently in breast cancer patients. Activating PIK3CA mutations confer resistance to human epidermal growth factor receptor 2 (HER2)-targeted treatments. In this study, we investigated whether PIK3CA mutations were correlated with treatment response or duration in patients with HER2-positive (HER2+) breast cancer.
Materials and Methods
We retrospectively reviewed the clinical information of patients with HER2+ breast cancer who received HER2-targeted therapy for early-stage or metastatic cancers. The pathologic complete response (pCR), progression-free survival (PFS), and overall survival were compared between patients with wild-type PIK3CA (PIK3CAw) and those with mutated PIK3CA (PIK3CAm). Next-generation sequencing was combined with examination of PFS associated with anti-HER2 monoclonal antibody (mAb) treatment.
Results
Data from 90 patients with HER2+ breast cancer were analyzed. Overall, 34 (37.8%) patients had pathogenic PIK3CA mutations. The pCR rate of the PIK3CAm group was lower than that of the PIK3CAw group among patients who received neoadjuvant chemotherapy for early-stage cancer. In the metastatic setting, the PIK3CAm group showed a significantly shorter mean PFS (mPFS) with first-line anti-HER2 mAb. The mPFS of second-line T-DM1 was lower in the PIK3CAm group than that in the PIK3CAw group. Sequencing revealed differences in the mutational landscape between PIK3CAm and PIK3CAw tumors.
Conclusion
Patients with HER2+ breast cancer with activating PIK3CA mutations had lower pCR rates and shorter PFS with palliative HER2-targeted therapy than those with wild-type PIK3CA. Precise targeted-therapy is needed to improve survival of patients with HER2+/PIK3CAm breast cancer. -
Citations
Citations to this article as recorded by
- Mapping the Kinase Inhibitor Landscape in Canine Mammary Carcinoma: Current Status and Future Opportunities
Małgorzata Chmielewska-Krzesińska
Animals.2026; 16(2): 232. CrossRef - Evolving concepts in HER2-low breast cancer: Genomic insights, definitions, and treatment paradigms
Whitney L. Hensing, Emily L. Podany, James J. Sears, Shaili Tapiavala, Andrew A. Davis
Oncotarget.2025; 16(1): 11. CrossRef - The Effect and Treatment of PIK3CA Mutations in Breast Cancer: Current Understanding and Future Directions
Young-Bin Cho, Kyoung-Sik Park
Medicina.2025; 61(3): 518. CrossRef - High frequency of the PIK3CA H1047L mutation in Indonesian breast cancer across molecular subtypes
Yan Wisnu Prajoko, Didik Setyo Heriyanto, Bayu Tirta Dirja, Susanto Susanto, Vincent Lau, Andrew Nobiantoro Gunawan, Brigitta Natasya Halim, Nur Dina Amalina, Rashi Kalra
PLOS One.2025; 20(5): e0322154. CrossRef - PIK3CA Mutations: Are They a Relevant Target in Adult Diffuse Gliomas?
Ana Tomás, Marta Pojo
International Journal of Molecular Sciences.2025; 26(11): 5276. CrossRef - Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients
Tatyana N. Sokolova, Grigory A. Yanus, Svetlana N. Aleksakhina, Yana V. Belysheva, Aleksandra P. Chernyakova, Yulia S. Zharnakova, Alisa S. Nikitina, Tatyana M. Stebneva, Aleksandr S. Martianov, Alla Yu. Goryainova, Mark I. Gluzman, Rashida V. Orlova, Ana
Cancers.2025; 17(11): 1833. CrossRef - Atractylenolide III attenuates acute kidney injury through phosphorylation of PIK3CA: Functional activation and molecular interaction analysis
Jianmin You, Shuai Sun, Dongxue Lv, Shuai Fan, Xuyang Yan, Meng Liu, Juan Jin, Wei Wang
Journal of Ethnopharmacology.2025; 353: 120368. CrossRef - Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches
Nigel P. Murray, Socrates Aedo
International Journal of Molecular Sciences.2025; 26(23): 11346. CrossRef - Predicting PIK3CA mutation in breast cancer with machine learning based multimodal image radiomics
Jiejie Yao, Xiaoyu Li, Weimin Chai, Anqi Li, Xiaosong Chen, Wei Zhou, Jianqiao Zhou
European Journal of Medical Research.2025;[Epub] CrossRef - Safety and efficacy of pyrotinib for HER‑2‑positive breast cancer in the neoadjuvant setting: A systematic review and meta‑analysis
Qian Ma, Bai Wei, Bi-Cheng Wang, Ganxin Wang, Xuan Zhou, Yan Wang
Oncology Letters.2024;[Epub] CrossRef - A novel PIK3CA hot-spot mutation in breast cancer patients detected by HRM-COLD-PCR analysis
Saoussen Debouki-Joudi, Wala Ben Kridis, Fatma Trifa, Wajdi Ayadi, Abdelmajid Khabir, Tahia Sellami-Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad-Gargouri
Breast Disease.2024; 43(1): 213. CrossRef - Liquid Biopsy in the Clinical Management of Cancers
Ho-Yin Ho, Kei-See (Kasey) Chung, Chau-Ming Kan, Sze-Chuen (Cesar) Wong
International Journal of Molecular Sciences.2024; 25(16): 8594. CrossRef - Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine
Eleonora Nicolò, Caterina Gianni, Giuseppe Curigliano, Carolina Reduzzi, Massimo Cristofanilli
Current Opinion in Oncology.2024; 36(6): 503. CrossRef - Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer
Li Yin, Gui-lai Chen, Zhuo Xiang, Yu-lin Liu, Xing-yu Li, Jing-wang Bi, Qiang Wang
Biomedicine & Pharmacotherapy.2023; 162: 114648. CrossRef - Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer
Kyoungmin Lee, Jongwon Lee, Jungmin Choi, Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee-Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, In Hae Park
Scientific Reports.2023;[Epub] CrossRef - Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA data
Haizhu Chen, Xingbin Hu, Daquan Wang, Ying Wang, Yunfang Yu, Herui Yao
Translational Oncology.2023; 37: 101738. CrossRef - Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review
Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B. Hannouf, Jacques Raphael, Phillip Blanchette, Abdullah Al-Humiqani, Monali Ray
Cancers.2023; 15(17): 4336. CrossRef - The clinical significance of HER2 expression in DCIS
Ioanna Akrida, Francesk Mulita
Medical Oncology.2022;[Epub] CrossRef
- Mapping the Kinase Inhibitor Landscape in Canine Mammary Carcinoma: Current Status and Future Opportunities
- 11,270 View
- 339 Download
- 15 Web of Science
- 18 Crossref
First
Prev
